FDA approves Elzonris ( tagraxofusp-erzs )
December 21, 2018, The U.S. Food and Drug Administration today approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older.
“Prior to today’s approval, there had been no FDA approved therapies for BPDCN. The standard of care has been intensive chemotherapy followed by bone marrow transplantation. Many patients with BPDCN are unable to tolerate this intensive therapy, so there is an urgent need for alternative treatment options,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.
BPDCN is an aggressive and rare disease of the bone marrow and blood that can affect multiple organs, including the lymph nodes and the skin. It often presents as leukemia or evolves into acute leukemia. The disease is more common in men than women and in patients 60 years and older.
The efficacy of Elzonris was studied in two cohorts of patients in a single-arm clinical trial. The first trial cohort enrolled 13 patients with untreated BPDCN, and seven patients (54%) achieved complete remission (CR) or CR with a skin abnormality not indicative of active disease (CRc). The second cohort included 15 patients with relapsed or refractory BPDCN. One patient achieved CR and one patient achieved CRc.
Common side effects reported by patients in clinical trials were capillary leak syndrome (fluid and proteins leaking out of tiny blood vessels into surrounding tissues), nausea, fatigue, swelling of legs and hands (peripheral edema), fever (pyrexia), chills and weight increase. Most common laboratory abnormalities were decreases in lymphocytes, albumin, platelets, hemoglobin and calcium, and increases in glucose and liver enzymes (ALT and AST). Health care providers are advised to monitor liver enzyme levels and for signs of intolerance to the infusion. Women who are pregnant or breastfeeding should not take Elzonris because it may cause harm to a developing fetus or newborn baby.
The labeling for Elzonris contains a Boxed Warning to alert health care professionals and patients about the increased risk of capillary leak syndrome which may be life-threatening or fatal to patients in treatment.
The FDA granted this application Breakthrough Therapy and Priority Review designation. Elzonris also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.
DRUG TRIALS SNAPSHOT SUMMARY:
What is the drug for?
ELZONRIS is a drug for treatment of patients 2 years and older who have a blastic plasmacytoid dendritic cell neoplasm (BPDCN).
BPDCN is a rare, rapidly progressing cancer of the bone marrow and blood that can affect multiple organs, including the skin, lymph nodes, spleen, and liver.
How is this drug used?
ELZONRIS is injected into a vein (intravenous) by a healthcare provider once daily on days 1 through 5 of a 21-day cycle. It takes about 15 minutes to receive an ELZONRIS infusion, and patients are hospitalized for the duration of the first cycle.
The dose depends on a patient’s weight.
What are the benefits of this drug?
Out of 13 patients who had never been treated for BPDCN, 7 patients (54%) achieved no evidence of disease (complete remission or CR) or no evidence of disease with some skin changes not indicative of active disease (CRc) after treatment with ELZONRIS.
Out of 15 patients with worsening or resistant BPDCN, 2 patients experienced no evidence of disease (CR) or no evidence of disease with some skin changes not indicative of active disease (CRc) after treatment with ELZONRIS.
The FDA granted the approval of Elzonris to Stemline Therapeutics.
Send inquiry online For more product information and prices
(Pharmaceutical Ingredients Manufacturer & Supplier & Exporter.)
After sending the online inquiry, we will reply you as soon as possible, if not get any response on time please contact us by Tel or Email. —— Green Stone SwissEmail: firstname.lastname@example.org
Tel: +86 592 5365887
WhatsApp: +86 189 6515 7632
Send inquiry online: